Operator
Thanks for standing by. My title is Jordan, and I will be your convention operator at this time. Presently, I might wish to welcome Vanda Prescribed drugs Inc. Earnings Convention Name. (Operator Directions) Thanks. I might now like to show the decision over to Kevin Moran, Vanda’s Chief Monetary Officer. Please go forward.
Kevin Moran
Senior VP, CFO & Treasurer
Thanks, Jordan. Good afternoon, and thanks for becoming a member of us to debate Vanda Prescribed drugs’ Fourth Quarter and Full 12 months 2025 efficiency. Our fourth quarter and full yr 2025 outcomes had been launched this afternoon and can be found on the SEC’s EDGAR system and on our web site, www.vandapharma.com. As well as, we’re offering stay and archived variations of this convention name on our web site. Becoming a member of me on at this time’s name is Dr. Mihael Polymeropoulos, our President, Chief Govt Officer and Chairman of the Board; and Tim Williams, our Basic Counsel. Following my introductory remarks, Mihael will replace you on our ongoing actions.
I’ll then touch upon our monetary outcomes earlier than we open the strains to your questions. Earlier than we proceed, I want to remind everybody that varied statements that we make on this name will likely be forward-looking statements inside the which means of federal securities legal guidelines.
Our forward-looking statements are based mostly upon present expectations and assumptions that contain dangers, modifications in circumstances and uncertainties. These dangers are described within the cautionary